In search of clinical neuroprotection after brain ischemia: the case for mild hypothermia (35 degrees C) and magnesium

Stroke. 2009 Jun;40(6):2236-40. doi: 10.1161/STROKEAHA.108.542381. Epub 2009 Apr 16.

Abstract

Background and purpose: Brain injury after stroke and other cerebral ischemic events is a leading cause of death and disability worldwide. Our purpose here is to argue in favor of combined mild hypothermia (35 degrees C) and magnesium as an acute neuroprotective treatment to minimize ischemic brain injury.

Methods: Drawing on our own experimental findings with mild hypothermia and magnesium, and in light of the moderate hypothermia trials in cardiac arrest/resuscitation and magnesium trials in ischemic stroke (IMAGES, FAST-Mag), we bring attention to the advantages of mild hypothermia compared with deeper levels of hypothermia, and highlight the existing evidence for its combination with magnesium to provide an effective, safe, economical, and widely applicable neuroprotective treatment after brain ischemia. With respect to effectiveness, our own laboratory has shown that combined mild hypothermia and magnesium treatment has synergistic neuroprotective effects and reduces brain injury when administered several hours after global and focal cerebral ischemia.

Conclusions: Even when delayed, combined treatment with mild hypothermia and magnesium has broad therapeutic potential as a practical neuroprotective strategy. It warrants further experimental investigation and presents a good case for assessment in clinical trials in treating human patients after brain ischemia.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Body Temperature
  • Brain Ischemia / drug therapy
  • Brain Ischemia / therapy*
  • Clinical Trials as Topic
  • Humans
  • Hypothermia, Induced*
  • Magnesium Compounds / therapeutic use*
  • Neuroprotective Agents / therapeutic use*

Substances

  • Magnesium Compounds
  • Neuroprotective Agents